Physician profile
Christopher E Coakley
NPI 1780750455
$3,066.54
in general payments reported to CMS, 2019-2025
16 companies · $252 in 2025
The $252 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $623 · 2020: $318 · 2021: $870 · 2022: $711 · 2023: $176 · 2024: $117 · 2025: $252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $544.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $543.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $609.85 | 2019-2025 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $591.08 | 2019-2022 | |
| Esperion Therapeutics, INC. | $511.49 | 2020-2024 | Nexletol, Nexlizet |
| Amgen INC. | $277.79 | 2019-2023 | Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $265.88 | 2021-2025 | |
| Pfizer INC. | $187.75 | 2019-2020 | |
| Abbvie INC. | $175.08 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $145.96 | 2020-2021 | |
| Alnylam Pharmaceuticals INC. | $96.45 | 2022 | |
| Medtronic Minimed, INC. | $45.52 | 2019-2020 | |
| Boston Scientific Corporation | $44.08 | 2025 | Spyglass, Wallflex Duodenal |
| Merck Sharp & Dohme LLC | $39.57 | 2019-2020 | |
| Lilly USA, LLC | $25.87 | 2019-2022 | |
| Medtronic, INC. | $20.38 | 2021 | |
| Antares Pharma, INC. | $15.47 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $14.32 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Coakley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.